Postmenopausal estrogen therapy and cardiovascular disease.

Abstract Background. The effect of postmenopausal estrogen therapy on the risk of cardiovascular disease remains controversial. Our 1985 report in the Journal, based on four years of follow-up, suggested that estrogen therapy reduced the risk of coronary heart disease, but a report published simultaneously from the Framingham Study suggested that the risk was increased. In addition, studies of the effect of estrogens on stroke have yielded conflicting results. Methods. We followed 48,470 postmenopausal women, 30 to 63 years old, who were participants in the Nurses' Health Study and who did not have a history of cancer or cardiovascular disease at base line. During up to 10 years of follow-up (337,854 person-years), we documented 224 strokes, 405 cases of major coronary disease (nonfatal myocardial infarctions or deaths from coronary causes), and 1263 deaths from all causes. Results. After adjustment for age and other risk factors, the overall relative risk of major coronary disease in women currently taki...

[1]  J. Manson,et al.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991, The New England journal of medicine.

[2]  A. Tosteson,et al.  Uncertainty about postmenopausal estrogen. Time for action, not debate. , 1991, The New England journal of medicine.

[3]  C. McDonald,et al.  Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. , 1991, BMJ.

[4]  P. Crosignani,et al.  Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women , 1991, The Lancet.

[5]  C. Christiansen,et al.  Influence of menopause on serum lipids and lipoproteins. , 1990, Maturitas.

[6]  P. Durrington,et al.  Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. , 1990, Atherosclerosis.

[7]  Graham A. Colditz,et al.  Menopause and Heart Disease , 1990 .

[8]  B Rosner,et al.  A prospective study of obesity and risk of coronary heart disease in women. , 1990, The New England journal of medicine.

[9]  K. Matthews,et al.  Menopause and Risk Factors for Coronary Heart Disease , 1989 .

[10]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[11]  W. Willett,et al.  Menopause and the risk of coronary heart disease in women. , 1987, The New England journal of medicine.

[12]  C. Caspersen,et al.  Physical activity and the incidence of coronary heart disease. , 1987, Annual review of public health.

[13]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[14]  W. Castelli,et al.  The triglyceride issue: a view from Framingham. , 1986, American heart journal.

[15]  D. Meldrum,et al.  Biologic effects of transdermal estradiol , 1986, The New England journal of medicine.

[16]  W. Kannel.  Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. , 1985, American heart journal.

[17]  P. Wilson,et al.  Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. , 1985, The New England journal of medicine.

[18]  G. Rose.  Incubation period of coronary heart disease. , 1982, British medical journal.

[19]  N. Kaplan.  Cardiovascular complications of oral contraceptives. , 1978, Annual review of medicine.

[20]  R. Gorlin,et al.  Premenopausal castration and documented coronary atherosclerosis. , 1971, The American journal of cardiology.

[21]  D. Hall,et al.  Time interval from castration in premenopausal women to development of excessive coronary atherosclerosis , 1967 .